Anthony A. Curro, MBA
Chief Executive Officer

Anthony Curro
Chief Executive Officer

Anthony is a seasoned business executive and entrepreneur, with over 25 years of experience in life sciences, technology, & finance. Prior to joining Immplacate, Anthony was CEO at Spruce Technology, where he led the firm through an extended period of high growth and expansion. In addition, he has held a number of senior level positions with global responsibilities, which include the medical device powerhouse Guidant, where he was involved in various aspects of the cardiovascular portfolio of products. Anthony also serves on the board at Xylyx, Inc., a leading biotechnology firm that specializes in native extracellular matrix (ECM) products for life sciences. He has specialized capabilities in sales, marketing, finance, operations, HR, R&D, and strategy. Anthony holds an MBA from Columbia Business School, Columbia University in New York.


Donna See, MBA, MPH
Strategic Dev. Advisor

Donna See
Strategic Development Advisor

Donna See is a Vice President at Allied Minds (Venture Capital firm), leading the firm’s partnerships with U.S. universities. Donna brings more than 14 years of experience in academic technology transfer, public-private partnerships, and early-stage technology development. She most recently served as Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally recognized leader in the field of academic tech transfer, and as the Founding Director of the Columbia-Coulter Translational Research Partnership. Prior to Columbia, Donna was Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop and acquire new healthcare technologies.


SengHo Jeon, MBA, MSc
President & CEO, Daewoong Ltd.

Gordana Vunjak-Novakovic
Scientific Co-Founder, Board Member

Gordana Vunjak-Novakovic is a University Professor (Columbia University highest rank), and The Mikati Foundation Professor of Biomedical Engineering and Medicine. She is a leading expert in engineering of human tissues for regenerative medicine, stem cell research (including mesenchymal stem cells), and study of human disease. With over 35,000 citations and h=118, she is one of the most highly cited individuals of all times in all disciplines. She has previously founded three other biotech companies (EpiBone, TARA Biosystems, Xylyx).

Among her recognitions, she is a Fellow of AAAS, a member of the Academia Europaea, National Academy of Engineering, National Academy Medicine, and National Academy of Inventors.


Holly Wobma, MD, PhD
Director, Research & Innovation
Scientific Co-Founder

Holly Wobma
Research Director, Scientific Co-Founder

Holly has been involved in biomedical research for 12 years. She recently completed an MD-PhD in Biomedical Engineering at Columbia University on a Presidential Scholarship. She has devoted her research to developing mesenchymal stromal cell immunotherapies and has expertise in cell therapies, immune modulation, and transplant tolerance. Prior to her MD-PhD, she worked in a stem cell manufacturing lab and has also conducted research in cancer nanotherapeutics. She graduated at the top of her college class at the University of Calgary (Canada), receiving the Muriel Kovitz Prize.

Beyond research, Holly has been engaged in the stem cell field for 5 years as a science writer, contributing monthly articles about the latest developments in regenerative medicine.


Gordana Vunjak-Novakovic, PhD
Scientific Co-Founder

SengHo Jeon
President & CEO, Daewoong Ltd.

SengHo Jeon was appointed President & CEO of Daewoong Pharmaceuticals in March of 2018. He is responsible for the general management of Daewoong, with particular focus on organic and strategic growth across the world.

Since Mr. Jeon joined Daewoong in 2000, he has held roles in business development, portfolio planning, and market access for both Korea and the global market. During his tenure as VP of the global business division, he managed the full value chain of global business, including: operation of overseas subsidiaries, off-shore manufacturing sites, strategic planning, business development, cross-border marketing, M&A, and international sales & trading. Focusing on the global expansion of Daewoong beyond Korean market, he led the company’s efforts to establish Daewoong's neurotoxin (NABOTATM) business worldwide, and he reinforced foreign direct investment including biologic business expansion to Indonesia and the establishment of a variety of cross-border commercial partnerships.